PROTEIN-POLYSACCHARIDE PNEUMOCOCCAL CONJUGATE VACCINES

该提案是为了开发一种多价的 肺炎球菌结合疫苗(S)，将是安全和 有效对抗链球菌引起的疾病 成人和婴儿都有肺炎。几种不同的 将研究替代载体蛋白，以优化 对糖类的抗体反应和增强感染的可能性 这种疫苗的研制成功(S)。疫苗(S)将 含有七种已知可导致严重疾病的血清型 无论是在这个国家还是在第三世界国家。恰如其分 将进行实验室测试以确定毒性， 致热性、过敏性和一般安全性 疫苗(S)。在动物身上进行安全性测试后，疫苗(S)将 在成人身上进行安全性和免疫原性测试，然后是 儿童和婴儿。预计这样的疫苗将 显著降低与以下疾病相关的发病率和死亡率 侵袭性肺炎球菌感染也对 婴儿中耳炎的发病率和费用 人口。

The proposal is for the development of a multivalent pneumococcal conjugate vaccine(s) which will be safe and effective in combating disease produced by Streptococcus pneumoniae in both adults and infants. Several different alternative carrier proteins will be examined to optimize the antibody response to the saccharide and enhance the likelihood for the successful development of this vaccine(s). The vaccine(s) will contain seven serotypes which are known to cause serious disease both in this country and third world countries. Appropriate laboratory tests will be performed to determine the toxicity, pyrogenicity, hypersensitivity and general safety of the vaccine(s). Following safety testing in animals, the vaccine(s) will be tested for safety and immunogenicity in adults, followed by children and infants. It is anticipated that such a vaccine will reduce significantly the morbidity and mortality associated with invasive pneumococcal infections and also have a great impact on the morbidity and costs associated with otitis media in the infant population.